Guzzi, Your AI's answer seems a bit off and confuses NICE threshold values with calculated outcome values. The 50K/QALY could be the highest effective threshold for end-of-life cancer drugs that extends life by 3 months (median). But it is NOT the drug’s calculated value. It is missing the long tail survival of years. So, 50K is at minimum misleading.
My AI says this:
Flawed Methodology: The Incremental Cost-Effectiveness Ratio (ICER) is not calculated using a drug's median survival benefit or any single point statistic. The proper assessment requires a complex economic model that calculates the total Quality-Adjusted Life Years (QALYs) gained by finding the entire area between the survival curves of the new drug and the standard of care. This model explicitly accounts for the high value of long-tail survivors (patients surviving 5, 10, or more years), which a simple comparison of median survival figures fails to capture adequately.
Confusing Threshold with Outcome: The £50,000/QALY figure is the highest effective threshold that the National Institute for Health and Care Excellence (NICE) might allow for a highly severe, life-limiting condition. It is not the drug's calculated value. Given the extremely high estimated cost of personalized therapy, the drug's calculated ICER, even when accounting for the long-tail benefit, is almost certainly significantly higher than £50,000/QALY. Presenting £50,000/QALY as the drug's outcome is therefore at minimum misleading.
Market Data 
Markets 
AI
